EIGHTH AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • November 14th, 2023 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This EIGHTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of November 13, 2023 (the “Effective Date”), by and between Chris Chapman, M.D. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of November 1, 2020, amended on December 18, 2020, January 8, 2021, February 10, 2021, November 24, 2021, August 30, 2022, January 1, 2023, and September 8, 2023 by and between Employee and the Company (the “Agreement”). Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
EMPLOYMENT MUTUAL SEPARATION AGREEMENTEmployment Mutual Separation Agreement • November 14th, 2023 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
THIS EMPLOYMENT MUTUAL SEPARATION AGREEMENT (this “Agreement”) is made and entered into as of the 13th day of November, 2023, by and between Paul M. Rivard, Esq. (“Employee”) and MyMD Pharmaceuticals, Inc. (“Company”).
fourTH AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • November 14th, 2023 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This fourTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of November 13, 2023 (the “Effective Date”), by and between Adam Kaplin, M.D. (“Employee”) and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of December 18, 2020, amended on February 10, 2021, November 24, 2021, and August 30, 2022 by and between Employee and the Company (the “Agreement”). Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
fIRST AMENDMENT TO AGREEMENTTo Agreement • November 14th, 2023 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This first AMENDMENT TO executive chairman AGREEMENT (this “Amendment”), is entered into as of November 13, 2023 (the “Effective Date”), by and between Christopher C. Schreiber (“Employee”) and MyMD Pharmaceuticals, Inc. (formerly known as Akers Biosciences, Inc.) (the “Company”), for the purpose of amending that certain Executive Chairman Agreement, dated as of January 31, 2020 by and between Employee and the Company (the “Executive Chairman Agreement”). Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have the meanings ascribed to such terms in the Executive Chairman Agreement.
